Cargando…
Are antiangiogenics a good ‘partner’ for immunotherapy in ovarian cancer?
Ovarian cancer (OC) is associated with poor survival because there are a limited number of effective therapies. Two processes key to OC progression, angiogenesis and immune evasion, act synergistically to promote tumor progression. Tumor-associated angiogenesis promotes immune evasion, and tumor-rel...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Netherlands
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7524856/ https://www.ncbi.nlm.nih.gov/pubmed/32691290 http://dx.doi.org/10.1007/s10456-020-09734-w |